LabStyle Innovations Corp is an offshore company that had developed Dario, a set of cloud-based diabetes monitoring devices that help people with diabetes to manage their own conditions.
Dario required re-registration with the NHS Drugs Tariff for Patient Appliances, following changing their nominated distributor for the UK market. The process might easily have become legally mired, consuming great cost and losing a lot of time for the company – unsustainable for a two-year-old company on a fast-track multinational growth trajectory.
IT Health Partner, Robin Stern, worked creatively and resourcefully to assure speedy compliance with the Drugs Tariff requirements and avoid legal pitfalls. The process also secured registration of a new Dario product set Dario-Lite which provided, in the meantime, a faster channel by which LabStyle supplied the self-help needed to people with diabetes.
Erez Raphael is Chairman and CEO of LabStyle Innovations Corp and DarioHealth Corp. “We were impressed by patients’ demand for our products in the UK market, but we were concerned to overcome obstacles in our supply chain. Robin Stern’s persistence, grasp of NHS processes and commercial realism enabled him to build effective relationships with the regulator, which won through.”Dario website